TSLP Recombinant Proteins and Antibodies

Thymic Stromal Lymphopoietin (TSLP) is a cytokine secreted by epithelial cells that plays a crucial role in allergic and inflammatory diseases such as asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. TSLP binds to its receptor complex (TSLPR and IL-7Rα) to activate the downstream JAK-STAT signaling pathway, inducing dendritic cell polarization and driving Th2-type immune responses. This leads to the release of inflammatory mediators and the maintenance of chronic inflammation. Because of its central role in the pathogenesis of multiple allergic diseases, TSLP has become an important emerging therapeutic target.

In recent years, drug development targeting TSLP has made remarkable progress. A representative example is Tezepelumab (jointly developed by AstraZeneca and Amgen), a humanized monoclonal antibody that blocks the interaction between TSLP and its receptor. Clinical studies have shown that Tezepelumab significantly reduces the risk of exacerbations in patients with severe asthma while improving lung function and symptom control. Results from Phase III clinical trials provided strong clinical evidence supporting TSLP-targeted therapy. In 2021, Tezepelumab was approved by the U.S. FDA for the treatment of moderate-to-severe asthma in patients aged 12 and older, making it the first TSLP inhibitor to reach the market.

Beyond Tezepelumab, several companies are exploring next-generation TSLP antagonists and combination therapies to expand indications to diseases such as atopic dermatitis and eosinophilic esophagitis. With a deeper understanding of TSLP signaling mechanisms, more precise and effective inhibitors are expected to emerge, offering new therapeutic options for patients with allergic and inflammatory disorders. Learn more about TSLP drug development >>

DIMA BIOTECH now provides recombinant TSLP and receptor-related proteins (human/mouse origin), monoclonal antibodies and reference antibodies (including biotin- or PE-labeled formats). We also offer comprehensive services such as custom protein/antibody development, antibody humanization, affinity maturation, and stable cell line construction. In addition, we have established a B-cell seed library targeting TSLP, enabling rapid screening and discovery of desired lead antibody molecules within 20 days.